Fresenius SE & Co KGaA
XETRA:FRE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.54
34.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Fresenius SE & Co KGaA
Fresenius SE & Co KGaA
Other Long-Term Assets
Fresenius SE & Co KGaA
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Other Long-Term Assets
€587m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-10%
|
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Other Long-Term Assets
€409.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-5%
|
|
|
Vita 34 AG
XETRA:V3V
|
Other Long-Term Assets
€12.5m
|
CAGR 3-Years
126%
|
CAGR 5-Years
35%
|
CAGR 10-Years
48%
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Other Long-Term Assets
HK$34.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Synlab AG
XETRA:SYAB
|
Other Long-Term Assets
€51.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Other Long-Term Assets
€409.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-5%
|
|
Fresenius SE & Co KGaA
Glance View
Fresenius SE & Co. KGaA, a titan in the global healthcare sector, traces its origins to a humble pharmacy in Frankfurt, Germany, in 1912. Since then, the company has evolved into a multifaceted healthcare conglomerate, positioning itself prominently in four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Each segment synergizes to form a comprehensive healthcare ecosystem. Fresenius Medical Care, the crown jewel of the group, stands as the world’s leading provider of products and services for individuals with renal diseases. This division, with a focus on dialyzing patients suffering from chronic kidney failure, operates a vast network of dialysis clinics and manufactures dialysis machines and related products that account for a significant portion of its income. Meanwhile, Fresenius Kabi, the pharmaceutical and medical device division, specializes in lifesaving drugs and technologies for critically and chronically ill patients. This division thrives on providing clinical nutrition, infusion therapy, and generics, positioning itself as a critical player in hospitals worldwide. Fresenius Helios is acknowledged as Europe's largest private hospital operator, managing a vast array of healthcare facilities that deliver inpatient and outpatient care, ensuring a steady stream of revenue through diverse healthcare services. Lastly, Fresenius Vamed provides a wide range of services for healthcare facilities, from project development and construction to full operational management, allowing the company to gain financial benefits from turnkey hospital solutions and infrastructure development. Through these concerted efforts, Fresenius SE & Co. KGaA cements its role as a key stakeholder in the global healthcare market, generating substantial revenues while addressing diverse medical needs across the globe.
See Also
What is Fresenius SE & Co KGaA's Other Long-Term Assets?
Other Long-Term Assets
587m
EUR
Based on the financial report for Sep 30, 2024, Fresenius SE & Co KGaA's Other Long-Term Assets amounts to 587m EUR.
What is Fresenius SE & Co KGaA's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-10%
Over the last year, the Other Long-Term Assets growth was -53%. The average annual Other Long-Term Assets growth rates for Fresenius SE & Co KGaA have been -45% over the past three years , -27% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet